Scan to download株式会社Ｖｅｒｉｔａｓ Ｉｎ Ｓｉｌｉｃｏ (130A) Earnings Releases & Disclosures
| Date | Type | Title | Files |
|---|---|---|---|
| 2026-11-11 | Earnings Release | Non-consolidated Financial Results for the Nine Months Ended September 30, 2026 [Under Japanese GAAP] | |
| 2026-11-11 | Presentation Materials | FY2026 Third Quarter Financial Briefing Materials | |
| 2026-11-11 | — | Revised Financial Forecast for the Fiscal Year Ending December 31, 2026 | |
| 2026-11-11 | — | Completion of Pre-development Consultation with PMDA and Future Prospects for Proprietary Drug Delivery System "Perfusio(R)" | |
| 2026-11-02 | — | Monthly Status of Exercise of #5 (with Exercise Price Adjustment Clause) and #6 to #9 Share Acquisition Rights(with Target Issue and Adjustment Optio | |
| 2026-11-02 | — | Syntara and Veritas In Silico sign MoU to Accelerate Joint Discovery Research for mRNA-Targeted Compounds | |
| 2026-10-29 | — | Notice of Completion of Payment for #5 and #6 to #9 Share Acquisition Rights by Third-Party Allotment | |
| 2026-10-19 | — | Notice Concerning Achievement of Research Milestone under Joint Drug Discovery with Toray Industries, Inc. | |
| 2026-08-05 | Earnings Release | Non-consolidated Financial Results for the Six Months Ended June 30, 2026 [Under Japanese GAAP] | |
| 2026-08-05 | Presentation Materials | Financial Briefing Materials - FY2026 Second Quarter | |
| 2026-08-03 | — | Joint Patent Application Filed for lncRNA-Targeting Drugs | |
| 2026-07-13 | — | Personnel Changes in Executive Officer |
TDnet keeps only 31 days; this site accumulates daily and cannot backfill earlier disclosures.